137 related articles for article (PubMed ID: 15317602)
21. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine an optimal indication for nateglinide.
Mori Y; Ishii H; Hikita M; Tajima N
Adv Ther; 2003; 20(6):352-9. PubMed ID: 15058753
[TBL] [Abstract][Full Text] [Related]
23. Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass.
Lucotti P; Monti L; Setola E; La Canna G; Castiglioni A; Rossodivita A; Pala MG; Formica F; Paolini G; Catapano AL; Bosi E; Alfieri O; Piatti P
Metabolism; 2009 Sep; 58(9):1270-6. PubMed ID: 19592054
[TBL] [Abstract][Full Text] [Related]
24. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
25. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
26. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
27. Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: associations with blood pressure and HDL cholesterol.
Woodman RJ; Playford DA; Watts GF
Diabetes Res Clin Pract; 2006 Jan; 71(1):59-67. PubMed ID: 16029909
[TBL] [Abstract][Full Text] [Related]
28. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
Gallagher A; Home PD
Diabetes Res Clin Pract; 2005 Mar; 67(3):196-203. PubMed ID: 15713351
[TBL] [Abstract][Full Text] [Related]
29. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
Mortensen UM; Nielsen-Kudsk JE; Sondergaard HM; Jakobsen P; Jensen BS; Schmitz O; Nielsen TT
Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219
[TBL] [Abstract][Full Text] [Related]
30. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Niemi M; Neuvonen M; Juntti-Patinen L; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2003 Jul; 74(1):25-31. PubMed ID: 12844132
[TBL] [Abstract][Full Text] [Related]
31. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
32. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
Monti LD; Setola E; Fragasso G; Camisasca RP; Lucotti P; Galluccio E; Origgi A; Margonato A; Piatti P
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E54-E59. PubMed ID: 16174656
[TBL] [Abstract][Full Text] [Related]
33. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
34. Impaired vascular function during short-term poor glycaemic control in Type 1 diabetic patients.
Sørensen VR; Mathiesen ER; Clausen P; Flyvbjerg A; Feldt-Rasmussen B
Diabet Med; 2005 Jul; 22(7):871-6. PubMed ID: 15975101
[TBL] [Abstract][Full Text] [Related]
35. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls.
Neri S; Signorelli SS; Torrisi B; Pulvirenti D; Mauceri B; Abate G; Ignaccolo L; Bordonaro F; Cilio D; Calvagno S; Leotta C
Clin Ther; 2005 Nov; 27(11):1764-73. PubMed ID: 16368447
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients.
Lucotti P; Setola E; Monti LD; Galluccio E; Costa S; Sandoli EP; Fermo I; Rabaiotti G; Gatti R; Piatti P
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E906-12. PubMed ID: 16772327
[TBL] [Abstract][Full Text] [Related]
37. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance.
Xiang GD; Sun HL; Zhao LS; Hou J; Yue L; Xu L
Clin Endocrinol (Oxf); 2008 May; 68(5):716-23. PubMed ID: 18070144
[TBL] [Abstract][Full Text] [Related]
38. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
39. A comparison of post-prandial changes in flow-mediated dilatation in patients with type 2 diabetes with and without macroalbuminuria.
Shand BI; Scott RS; Florkowski CM; Reynolds ; Ikram H
Diabetes Nutr Metab; 2001 Aug; 14(4):201-6. PubMed ID: 11716289
[TBL] [Abstract][Full Text] [Related]
40. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
Whitelaw DC; Clark PM; Smith JM; Nattrass M
Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
